Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the company is a Phase IIb-ready Berger disease therapy from Merck KGaA that could be disease-modifying.  

Trucode Gene Repair Inc. debuted in September 2019 with $34 million to develop a nuclease-free, viral vector-independent gene editing technology from Peter Glazer’s lab at Yale University. The company, the third to launch based on Glazer’s technology, hoped its innovations in chemistry and delivery technology could help it succeed where the others failed...